drugset / Trial / NCT01259648

Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects

NCT01259648

Phase 4 Completed 75 enrolled Nîmes University Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective is to determine whether, during a rapid sequence intubation by etomidate, and succinylcholine Sellick maneuver, the administration of remifentanil at 2 different dosages (0.5 and 1.0 microgram per kg body weight), reduces potentially dangerous reactional tachycardia.

Timeline

Start
2011-03-09
Primary completion
2014-05-20
Completion
2014-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 0.5 ug/kg
Subject Remifentanil Small molecule 1 ug/kg